Genomic Health gaining fast in genomic testing...just wait till prostate
Prolaris faces direct competition from Oncotype DX, the test provided by Genomic Health. In addition to checking the severity of prostate cancer, Oncotype DX is also approved for checking the severity of breast and colon cancer in the patient. Genomic introduced this test in May 2013, so Prolaris will have the first mover advantage. However, the additional features of Oncotype DX will bring in better returns for Genomic Health compared to Prolaris for Myriad Genetics.
To develop the Oncotype DX prostate cancer test further, Genomic Health conducted research studies on more than 700 patients. In these studies, scientists analyzed genes in prostate cancer samples of these 700 patients. The development studies resulted in discovery of 81 genes from prostate cancer samples. These genes will go through additional research before moving on to clinical usage, which will help improve the Oncotype DX test in the future. These developments are enough to present strong headwinds for Prolaris. The additional features and developmental studies are popularity factors for the Oncotype DX test, and more than 19,000 physicians in over 70 countries ordered 375,000 Oncotype DX tests as of June 30, 2013.
The flagship program BRACanalysis maintained the company's dominance for past ten years, and its legacy is expected to continue with myRisk. BRACanalysis is also being used currently as a companion test with Tesaro's niraparib. Prolaris is another key factor for Myriad Genetics, but the competitive pressure from Genomic Health is a headwind for Prolaris. These factors hint at a "hold" until Myriad Genetics makes any substantial moves.
Very poorly written. This author seems to think the Oncotype DX test is the same for all cancers. When I read this last week I discounted any implied conclusions. I have yet to see a good discussion on the pros and cons of each company's prostate test.
I hate how Yahoo nests and orders posts. You'll have to put in order my response but basically I quoted a nice discussion of Myriad's prostate test and how a urology might have trouble fitting it into their current decision tree. I am a physician who has discussed this with urologists and anyone I talk to is waiting for their Society to publish treatment guidelines that incorporates one of these tests. What I want to see is a dispasionate, non-biased discussion of both tests.
BTW, I am and have been very long this stock for some time. Most of my shares cost me less than $15.